|
|
ƯÀÌÄÉÀ̽º À¯¹æ¾ÏÀ̶ó°í Çؼ Áú¹®µå¸³´Ï´Ù |
|
|
|
ÀÛ¼ºÀÚ : ¾Æ¸®¼Û |
ÀÛ¼ºÀÏ : 2024-04-02 [21:14]Á¶È¸ : 281 |
|
|
|
|
|
|
|
¾È³çÇϼ¼¿ä ±³¼ö´Ô Àú´Â °Üµå¶ûÀÌ °¡¿îµ¥ 1¼¾Ä¡ Á¤µµÀÇ ¸Û¿ïÀÌ ÀâÇô¼ °³ÀÎ º´¿ø¿¡¼ Ç¥Áö³¶Á¾À¸·Î Áø·á¸¦ ¹Þ°í ¸Û¿ïÀ» ¶¼¾î³»´Â ¼ö¼úÀ» ¹ÞÀº ÈÄ Á¶Á÷°Ë»ç¸¦ Çߴµ¥ È£¸£¸ó ¾ç¼º À¯¹æ¾Ï Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù ¤·¤¸´ëÇб³ º´¿ø¿¡¼ ¼ö¼ú Àü °Ë»ç¸¦ ¹Þ°í ´ã´ç ±³¼ö´ÔÀ» ¸¸³µ´Âµ¥ »À,¸²ÇÁ¿Í ´Ù¸¥ Àå±â´Â ÀüÀÌ°¡ ¾øÀ½À» À̾߱â ÇÏ¼Ì°í º´±â´Â 1±â Á¤µµ·Î ÆÇ´ÜÇϼ̽À´Ï´Ù ´ã´ç ±³¼ö´Ô ¸»¾¸À¸·Ð °Üµå¶ûÀÌ¿¡¼ À¯¹æ¾ÏÀ» ¹ß°ßÇÑ »ç·Ê°¡ ±ØÈ÷ µå¹°´Ù´Â À̾߱⸦ Çϼ̰í, ¼ö¼ú ½Ã °Üµå¶ûÀÌ Á¶Á÷ ºÎºÐ¿¡ ÀÖ´Â Á¤»ó Á¶Á÷À» ´õ ¶¼¾î³»¼ °æ°è ºÎºÐ¿¡ ¾ÏÀÌ ÀÖ´ÂÁö Á¤È®ÇÑ º´±â¸¦ È®ÀÎÇÏÀÚ°í Çϼ̽À´Ï´Ù
±³¼ö´Ôµµ Àú¿Í °°Àº »ç·ÊÀÇ À¯¹æ¾Ï ȯÀÚ¸¦ º¸½ÅÀûÀÌ ÀÖÀ¸½Å°¡¿ä? ƯÀÌÄÉÀ̽º¶ó´Â ¸»¾¸À» Çϼż ¼ö¼ú¿¡ °üÇÑ ±³¼ö´ÔÀÇ »ý°¢À» µé¾îº¸°í ½Í¾î¼ ÀÌ·¸°Ô Áú¹®µå¸³´Ï´Ù
¾Æ·¡´Â Á¶Á÷º´¸® °á°ú ¼öÄ¡ÀÔ´Ï´Ù.
º´¸®ÇÐÀû Áø´Ü:À¯¹æ, ¿ÞÂÊ, ÀýÁ¦: Ư¼ö À¯ÇüÀÌ ¾Æ´Ñ ħÀ±¼º À¯°ü¾Ï(Invasive carcinoma of no special type, ductal)Å©±â: ¾à 12x11mmºÎÀ§: °Üµå¶ûÀÌ ÇÙ µî±Þ(Nuclear grade): 2 (Áß°£µµ ºÐÈ) Á¶Á÷ÇÐÀû µî±Þ(Histologic grade, Nottingham Histologic score): 1+1+1=3 (Á¡¼ö 6) ¼¼°ü Çü¼º(Tubule formation): 1 ÇÙ´ÙÇü¼º(Nuclear pleomorphism): 1 ºÐ¿·ü(Mitotic rate): 1 »óÇdz»¾Ï(EIC) Á¸Àç: ¾øÀ½(EIC negative) ÀýÁ¦ °æ°è(Resection margins): È®ÀÎ ºÒ°¡ ¸²ÇÁ°ü ħ½À(Lymphovascular invasion): Á¸Àç ½Å°æÁÖº¯ ħ½À(Perineural invasion): ¾øÀ½ ¹Ì¼¼¼®È¸È(Microcalcification): Á¸Àç ¸é¿ªÁ¶Á÷ÈÇÐ °Ë»ç(Immunohistochemistry): Ãß°¡ º¸°í¼¿¡ µû¸§ Ãß°¡ º¸°í¼(2024³â 3¿ù 20ÀÏÀÚ)ÀÇ °á°ú: ¿¡½ºÆ®·Î°Õ ¼ö¿ëü(ER): ¾ç¼º(80%, Áß°£ °µµ), Allred Á¡¼ö 7: °µµ 2 + ºñÀ² 5 ÇÁ·Î°Ô½ºÅ×·Ð ¼ö¿ëü(PR): ¾ç¼º(80%, °ÇÑ °µµ), Allred Á¡¼ö 8: °µµ 3 + ºñÀ² 5 HER2: À½¼º(Á¡¼ö 0) E-cadherin: ¾ç¼º Ki-67 : 25%
(¸ð¹ÙÀÏ¿¡¼ ÀÛ¼ºµÇ¾ú½À´Ï´Ù) |
|
|
|
|
|